EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical performance of two commercially available rapid antigen tests for influenza, RSV, and SARS-CoV-2 diagnostics

Laura E Savolainen iD, Joanna Peltola, Risto Hilla, Tapio Åman, Markku Broas, Ilkka S Junttila iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.01630-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Laura E Savolainen und 5 weiteren Autor:innen. Beteiligte Einrichtung: NordLab, Oulu, Finland. Hauptthemen laut MEDLINE: Sensitivity and Specificity, Respiratory Syncytial Virus Infections, COVID-19, Influenza, Human. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Competitive State Research Financing of the Expert Responsibility Areas of Fimlab Laboratories, NordLab, Tampere Tuberculosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapid antigen tests (RATs) might provide rapid, low-cost, and easy-to-perform choice to nucleic-acid amplification methods (NAAT) in point-of-care (POC) diagnostics of respiratory infections. The clinical performance of two commercial combo-RATs for influenza A and B, respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) POC diagnostics, was assessed. RAT and real-time-PCR (RT-PCR) analysis were performed on 620 patients admitted to the emergency department due to respiratory symptoms. The sensitivity and specificity of the RATs compared with RT-PCR results were studied. The sensitivity of the RATs with respect to symptom duration was also estimated. The tested RAT1 showed sensitivities of 98.68%, 73,53%, and 44.44% for SARS-CoV-2, influenza A, and RSV, respectively, when the cycle threshold (Ct) values were

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sensitivity and SpecificityRespiratory Syncytial Virus InfectionsCOVID-19Influenza, HumanSARS-CoV-2Antigens, ViralHumansMiddle AgedMaleAdultFemaleAgedInfluenza A virusPoint-of-Care TestingYoung AdultAdolescentAged, 80 and overChild

Stichwörter der Autor:innen

SARS-CoV-2antigen testinfluenzarespiratory syncytial virus

Substanzen

Antigens, Viral

Autor:innen und Institutionen

  • NordLab, Oulu, Finland.
  • NordLab, Rovaniemi, Finland.
  • Mehiläinen Länsi-Pohja, Kemi, Finland.
  • Wellbeing Cervices County of Lapland, Rovaniemi, Finland.
  • University of Oulu, Oulu, Finland.
  • Tampere University, Tampere, Finland.

ORCID-Profile: Laura E Savolainen, Ilkka S Junttila

Förderung

  • Competitive State Research Financing of the Expert Responsibility Areas of Fimlab Laboratories
  • NordLab
  • Tampere Tuberculosis Foundation

Zitieren

APA

Savolainen, L. E., Peltola, J., Hilla, R., Åman, T., Broas, M., & Junttila, I. S. (2025). Clinical performance of two commercially available rapid antigen tests for influenza, RSV, and SARS-CoV-2 diagnostics. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01630-24

Vancouver

Savolainen LE, Peltola J, Hilla R, Åman T, Broas M, Junttila IS. Clinical performance of two commercially available rapid antigen tests for influenza, RSV, and SARS-CoV-2 diagnostics. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01630-24

BibTeX
@article{Savolainen2025,
  author = {Savolainen, Laura E and Peltola, Joanna and Hilla, Risto and Åman, Tapio and Broas, Markku and Junttila, Ilkka S},
  title = {Clinical performance of two commercially available rapid antigen tests for influenza, RSV, and SARS-CoV-2 diagnostics},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.01630-24}
}
Kostenlos starten →